An examination of the study, published in the Archives of General Psychiatry, revealed why it actually ended at week four. At week eight, the Xanax patients were doing no better than the placebo patients and, when the taper-off period began, the Xanax patients proved to be in far worse shape. Xanax patients were tortured by intense withdrawal symptoms and a 350 percent increase in the number of “panic attacks.”
Yet how did the study’s summary describe it? As an unqualified success. And that was all the FDA needed.
Further clouding the truth, Klerman wrote a lengthy introduction in which he claimed Upjohn had gone to great lengths to ensure scientific objectivity and quality.
What Klerman didn’t say was certainly misleading. The reader assumed he was reading an independent review from the former director of NIMH — not essentially a paid endorsement. No mention was made that Klerman had been a paid consultant to Upjohn since 1983.
Upjohn money also may have ensured that the Archives of General Psychiatry would not subject the study or its introduction to a critical eye. Its editor in chief, psychiatrist Daniel X. Freedman, became a paid consultant to the Upjohn Company the year the study was published.
Continued...
| Previous | Glossary of Scientology Terms | Contents | Next |
| Your view on this Scientology Website | Scientology Related Sites | Bookstore | Church of Scientology Freedom Magazine |
editor@freedommag.org © 1999-2008 Church of Scientology International. All Rights Reserved.
